Business
ANGLE's Parsortix system showcased at AACR 2021
ANGLE's Parsortix system showcased at AACR 2021.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0508V\n Angle PLC\n 12 April 2021\n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 12 April 2021\n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n ANGLE'S PARSORTIX SYSTEM SHOWCASED IN POSTER PRESENTATIONS AT LEADING CANCER CONFERENCE \n \n \n \n \n \n Publication of study results demonstrating the capabilities of two new assays in clinical samples at AACR 2021\n \n \n \n \n \n Immunotherapy assay enables determination of PD-L1 status in significant proportion of patients and could guide personalised treatment selection \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, \n is pleased to announce that two poster presentations showcasing the Parsortix® system are being presented at the American Association for Cancer Research Conference (AACR) 2021, being held as a virtual meeting on 10-15 April 2021 and then 17-21 May 2021. These posters present findings from key studies undertaken as part of ANGLE's clinical development programme.\n \n \n \n \n \n The first poster, \"Mesenchymal markers: the new avenue for circulating tumour cells detection\", reports on the performance of ANGLE's new epithelial-to-mesenchymal transition (EMT) assay to isolate and identify both epithelial and mesenchymal circulating tumor cells (CTCs) in 47 metastatic breast cancer (MBC) and 48 non-small cell lung cancer (NSCLC) patients. \n \n \n \n \n \n Unlike tissue biopsy, a liquid biopsy harvesting CTCs from peripheral blood allows the routine, repeat testing and characterisation of cancer at genetic (DNA), transcriptional (RNA) and protein levels. Most CTC isolation systems, including the market leader, are based on epitope-dependent CTC capture using epithelial markers. However, it is known that tumour cells can undergo EMT resulting in these clinically relevant cells being missed by epitope-dependent systems. ANGLE's Parsortix system addresses this major limitation in other systems by its epitope-independent proprietary approach to capture all phenotypes of cancer cell in the blood circulation.\n \n \n \n \n \n This study highlighted the importance of the inclusion of mesenchymal markers into CTC characterisation, as 25-38% of CTCs captured by the Parsortix system expressed mesenchymal markers w...